

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hodge et al.

Application No. 10/590,844

Filed: August 24, 2006

Confirmation No. 8385

For: SCREENING AGENTS THAT DECREASE
PATHOGENICITY BY DECREASING
RAB11A ACTIVITY

FILED VIA EFS

Examiner: Sheridan Swope

Art Unit: 1652

Attorney Reference No. 6395-68026-07

FILED VIA EFS
COMMISSIONER FOR PATENTS

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)

Listed on the accompanying form PTO-1449 and submitted herewith is one English-language document. Applicants respectfully request that this document be listed as a reference cited on the issued patent.

Applicants filed this Information Disclosure Statement (IDS) before the mailing of a first Office action after the filing of request for continued examination under § 1.114. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By /Karri Kuenzli Bradley/
Karri Kuenzli Bradley, Ph.D.
Registration No. 56,300

cc: Docketing